Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003292 · ClinicalTrials.gov registry record · Phase 2
S9624 Ifosfamide in Treating Patients With Meningeal Tumors
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00003292: Clinical Trial Phase 2 study, sponsored by SWOG Cancer Research Network.
NCT00003292 is a Phase 2 study that was terminated before completion, run by SWOG Cancer Research Network. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003292, a Phase 2 study, was terminated before completion, sponsored by SWOG Cancer Research Network.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ifosfamide in treating patients with meningeal tumors that have recurred or that cannot be removed surgically.
Interventions
- DRUG ifosfamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 1998-07 |
| Est. Completion | 2004-01 |
| Phase | Phase 2 |
Why NCT00003292 stopped before completion
NCT00003292 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which ifosfamide is the first listed.
NCT00003292 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003292 about?
NCT00003292 is a clinical study titled "S9624 Ifosfamide in Treating Patients With Meningeal Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ifosfamide in treating patients with meningeal tumors that have recurred or that cannot be removed surgically.
What is the current status of trial NCT00003292?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 1998-07. Estimated completion is 2004-01.
What interventions are being tested in trial NCT00003292?
The interventions under investigation include: ifosfamide (DRUG).
Who is sponsoring clinical trial NCT00003292?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00003292's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia